Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from Akebia Therapeutics

< Previous 1 2 Next >
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to purchase... 
Tickers AKBA
From PR Newswire
Akebia Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive... 
Tickers AKBA
From PR Newswire
Akebia Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Updates
- Full-year 2020 net product revenue increases to $128.9 million, up 16% from 2019 
Tickers AKBA
From PR Newswire
Akebia Therapeutics Appoints LeAnne M. Zumwalt, Dialysis Industry Leader, to Board of Directors
Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of LeAnne M. Zumwalt to its Board of... 
Tickers AKBA
From PR Newswire
Akebia Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results... 
Tickers AKBA
From PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 19 newly-hired employees options to purchase an... 
Tickers AKBA
From PR Newswire
Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, President and Chief... 
Tickers AKBA
From PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase... 
Tickers AKBA
From PR Newswire
Akebia Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, President and Chief... 
Tickers AKBA
From PR Newswire
AkebiaShares Program: Current Approaches for Managing Hyperphosphatemia and Caring for Patients via Telehealth
Virtual Panel of Nephrology Care Professionals to Share Insights and Experiences Managing Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis 
Tickers AKBA
From PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 7 newly-hired employees options to purchase an... 
Tickers AKBA
From PR Newswire
Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will participate in the Piper... 
Tickers AKBA
From PR Newswire
Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it ranked number 10 on Deloitte's... 
Tickers AKBA
From PR Newswire
Akebia Announces Manuscript Highlighting Global Phase 3 INNO2VATE Program Rationale, Study Design and Baseline Characteristics Published in Peer-Reviewed Medical Journal
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the publication of a manuscript... 
Tickers AKBA
From PR Newswire
Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates
- Presented positive global Phase 3 data for vadadustat from the INNO2VATE program for the treatment of anemia due to chronic kidney disease in adult patients on dialysis at ASN Kidney Week 
Tickers AKBA
From PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 6 newly-hired employees options to purchase an... 
Tickers AKBA
From PR Newswire
Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results... 
Tickers AKBA
From PR Newswire
Akebia Presents Results from its PRO2TECT Global Phase 3 Program of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients Not on Dialysis During Late-Breaking Session
- As previously announced, PRO2TECT data show vadadustat achieved primary and key secondary efficacy endpoints in each study, but did not meet the primary safety endpoint 
Tickers AKBA
From PR Newswire
Akebia Presents Results from its INNO2VATE Global Phase 3 Program; Demonstrated Efficacy and Cardiovascular Safety of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Pati
- INNO2VATE data presented at American Society of Nephrology Kidney Week 2020 Reimagined 
Tickers AKBA
From PR Newswire
Akebia to Present Global Phase 3 Vadadustat Data at American Society of Nephrology Kidney Week 2020 Reimagined
- Phase 3 data from INNO2VATE program in dialysis and PRO2TECT program in non-dialysis accepted for oral presentation 
Tickers AKBA
From PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 11 newly-hired employees options to purchase an... 
Tickers AKBA
From PR Newswire
Akebia Therapeutics Announces September 2020 Investor Conference Schedule
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will participate in the... 
Tickers AKBA
From PR Newswire
Akebia Therapeutics Announces Top-Line Results from its PRO2TECT Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients Not on Dialysis
- PRO2TECT achieves primary and key secondary efficacy endpoints 
Tickers AKBA
From PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 10 newly-hired employees options to purchase an... 
Tickers AKBA
From PR Newswire
Akebia Therapeutics Announces First Commercial Launch of VAFSEO™ (vadadustat tablets), a New Oral Treatment for Anemia Due to Chronic Kidney Disease, in Japan
VAFSEO Launch Marks Availability of Convenient Once-Daily Oral Treatment for Adult Patients on Dialysis and Not on Dialysis in Japan 
Tickers AKBA
From PR Newswire
Akebia Reports Second Quarter 2020 Financial Results
Tickers AKBA
From PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase... 
Tickers AKBA
From PR Newswire
Akebia Therapeutics to Report Second Quarter 2020 Financial Results
Company announces database lock and plans to report top-line data from global Phase 3 PRO2TECT program of vadadustat for treatment of anemia due to chronic kidney disease in adult patients not on... 
Tickers AKBA
From PR Newswire
Akebia Announces Initiation of Investigator-Sponsored Study Evaluating Vadadustat for Prevention and Treatment of ARDS in Patients Hospitalized with COVID-19
The University of Texas Health Science Center at Houston to conduct study with up to 300 patients to evaluate use of Akebia's investigational drug, vadadustat, as potential therapy to lessen the... 
Tickers AKBA
From PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase... 
Tickers AKBA
From PR Newswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.